Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2018, Article ID 4098210, 7 pages
https://doi.org/10.1155/2018/4098210
Clinical Study

Hemodynamic Evaluation of Nonselective β-Blockers in Patients with Cirrhosis and Refractory Ascites

1Multivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology, Padua University Hospital, Padua, Italy
2Department of Medicine, Padua University Hospital, Padua, Italy
3Laboratory Medicine, Department of Medical and Surgical Sciences, University of Padua, Padua, Italy

Correspondence should be addressed to Marco Senzolo; moc.liamtoh@oloznesocram

Received 1 March 2018; Accepted 10 April 2018; Published 9 May 2018

Academic Editor: Francesco Selvaggi

Copyright © 2018 Alberto Ferrarese et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. A. Runyon, “Management of adult patients with ascites due to cirrhosis: an update,” Hepatology, vol. 49, no. 6, pp. 2087–2107, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. G. D'Amico, A. Morabito, M. D'Amico et al., “Clinical states of cirrhosis and competing risks,” Journal of Hepatology, vol. 68, no. 3, pp. 563–576, 2018. View at Publisher · View at Google Scholar
  3. R. Moreau, P. Delegue, F. Pessione et al., “Clinical characteristics and outcome of patients with cirrhosis and refractory ascites,” Liver International, vol. 24, no. 5, pp. 457–464, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Bosch, R. J. Groszmann, and V. H. Shah, “Evolution in the understanding of the pathophysiological basis of portal hypertension: how changes in paradigm are leading to successful new treatments,” Journal of Hepatology, vol. 62, no. 1, pp. S121–S130, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Ginès, G. Fernández-Esparrach, A. Monescillo et al., “Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis,” Gastroenterology, vol. 111, no. 4, pp. 1002–1010, 1996. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Sersté, C. Melot, C. Francoz et al., “Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites,” Hepatology, vol. 52, no. 3, pp. 1017–1022, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Sersté, C. Francoz, F. Durand et al., “Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study,” Journal of Hepatology, vol. 55, no. 4, pp. 794–799, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. V. Hernández-Gea, C. Aracil, A. Colomo et al., “Development of ascites in compensated cirrhosis with severe portal hypertension treated with β-blockers,” The American Journal of Gastroenterology, vol. 107, no. 3, pp. 418–427, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Mandorfer, S. Bota, P. Schwabl et al., “Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis,” Gastroenterology, vol. 146, no. 7, pp. 1680–1690.e1, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Senzolo, E. Cholongitas, P. Burra et al., “β-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis,” Liver International, vol. 29, no. 8, pp. 1189–1193, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. K. P. Moore, F. Wong, P. Gines et al., “The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club,” Hepatology, vol. 38, no. 1, pp. 258–266, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. J. C. Garcia-Pagan and N. D. Grace, “Session 5 – primary prophylaxis,” in Portal Hypertension III: Proceedings of the Third Baverno International Consensus Workshop on Definitions, Methodology and Therapeutic Strategies, pp. 127–133, Blackwell Science Ltd, Oxford, UK, 2001. View at Publisher · View at Google Scholar
  13. R. Richard, E. Lonsdorfer-Wolf, A. Charloux et al., “Non-invasive cardiac output evaluation during a maximal progressive exercise test, using a new impedance cardiograph device,” European Journal of Applied Physiology, vol. 85, no. 3-4, pp. 202–207, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Casiglia, P. Palatini, G. Colangeli et al., “24 h rhythm of blood pressure and forearm peripheral resistance in normotensive and hypertensive subjects confined to bed,” Journal of Hypertension, vol. 14, no. 1, pp. 47–52, 1996. View at Publisher · View at Google Scholar
  15. E. Casiglia, G. Ginocchio, V. Tikhonoff et al., “Blood pressure and metabolic profile after surgical menopause: comparison with fertile and naturally-menopausal women,” Journal of Human Hypertension, vol. 14, no. 12, pp. 799–805, 2000. View at Publisher · View at Google Scholar
  16. E. Casiglia, A. Pizziol, V. Tikhonoff et al., “The 24-hour rhythm of blood pressure differs from that of leg hemodynamics in orthotopic heart transplant recipients,” American Heart Journal, vol. 140, no. 6, pp. 941–944, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Ginès, V. Arroyo, V. Vargas et al., “Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites,” The New England Journal of Medicine, vol. 325, no. 12, pp. 829–835, 1991. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Coll, M. C. Vila, L. Molina, M. D. Gimenez, C. Guarner, and R. Solà, “Mechanisms of early decrease in systemic vascular resistance after total paracentesis: influence of flow rate of ascites extraction,” European Journal of Gastroenterology & Hepatology, vol. 16, no. 3, pp. 347–353, 2004. View at Google Scholar
  19. J. Sola-Vera, J. Miñana, E. Ricart et al., “Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites,” Hepatology, vol. 37, no. 5, pp. 1147–1153, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. M. C. Vila, R. Solà, L. Molina et al., “Hemodynamic changes in patients developing effective hypovolemia after total paracentesis,” Journal of Hepatology, vol. 28, no. 4, pp. 639–645, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Krag, S. Møller, A. K. Burroughs, and F. Bendtsen, “Betablockers induce cardiac chronotropic incompetence,” Journal of Hepatology, vol. 56, no. 1, pp. 298-299, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Reiberger and M. Mandorfer, “Beta adrenergic blockade and decompensated cirrhosis,” Journal of Hepatology, vol. 66, no. 4, pp. 849–859, 2017. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Nasr, A. Hassan, S. Ahmed, and A. Serwah, “Predictors of large volume paracantesis induced circulatory dysfunction in patients with massive hepatic ascites,” Journal of Cardiovascular Disease Research, vol. 1, no. 3, pp. 136–144, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. B. Appenrodt, A. Wolf, F. Grünhage et al., “Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study,” Liver International, vol. 28, no. 7, pp. 1019–1025, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Kalantari, J. N. Chang, C. Ronco, and M. H. Rosner, “Assessment of intravascular volume status and volume responsiveness in critically ill patients,” Kidney International, vol. 83, no. 6, pp. 1017–1028, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Piccoli and for the Italian Hemodialysis-Bioelectrical Impedance Analysis (HD-BIA) Study Group, “Identification of operational clues to dry weight prescription in hemodialysis using bioimpedance vector analysis,” Kidney International, vol. 53, no. 4, pp. 1036–1043, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Davenport, B. Argawal, G. Wright et al., “Can non-invasive measurements aid clinical assessment of volume in patients with cirrhosis?” World Journal of Hepatology, vol. 5, no. 8, pp. 433–438, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. R. P. Mookerjee, M. Pavesi, K. L. Thomsen et al., “Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure,” Journal of Hepatology, vol. 64, no. 3, pp. 574–582, 2016. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Krag, R. Wiest, A. Albillos, and L. L. Gluud, “The window hypothesis: haemodynamic and non-haemodynamic effects of β-blockers improve survival of patients with cirrhosis during a window in the disease,” Gut, vol. 61, no. 7, pp. 967–969, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. P. S. Ge and B. A. Runyon, “The changing role of beta-blocker therapy in patients with cirrhosis,” Journal of Hepatology, vol. 60, no. 3, pp. 643–653, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Ferrarese, E. Tsochatzis, A. K. Burroughs, and M. Senzolo, “Beta-blockers in cirrhosis: therapeutic window or an aspirin for all?” Journal of Hepatology, vol. 61, no. 2, pp. 449-450, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. U. Thalheimer, J. Christie, and A. K. Burroughs, “Benefits of beta blockade beyond bleeding prophylaxis and the role of adherence,” The American Journal of Gastroenterology, vol. 107, no. 10, p. 1593, 2012. View at Publisher · View at Google Scholar · View at Scopus